#H2 Receptor Antagonist Market CAGR

[insightfulblogz]

Peptic Ulcer Drugs Market Applications and Future Prospects Details for Business Development, 2032

Peptic ulcers, which include gastric and duodenal ulcers, are painful sores that develop in the lining of the stomach or the upper part of the small intestine. The primary causes of these ulcers are infection with Helicobacter pylori and the long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs). The treatment landscape for peptic ulcers has evolved significantly over the years, incorporating a range of therapeutic options. Proton pump inhibitors (PPIs), histamine-2 (H2) receptor antagonists, and antibiotics are among the most commonly prescribed medications. These drugs work synergistically to reduce stomach acid, promote healing, and eliminate the underlying bacterial infection. With a focus on enhancing patient outcomes, pharmaceutical companies are investing in research to develop more effective formulations and novel therapies, ultimately improving the quality of life for millions affected by this condition.

The Peptic Ulcer Drugs Market size was USD 4.87 Billion in 2023 and is expected to reach USD 6.43 Billion by 2032 and grow at a CAGR of 3.16% over the forecast period of 2024-2032.

Future Scope

The future of peptic ulcer drug therapy appears promising, driven by advancements in pharmacology and a deeper understanding of ulcer pathophysiology. Ongoing research is exploring the potential of novel drug combinations that target H. pylori resistance and improve eradication rates. Furthermore, the development of personalized medicine approaches, which tailor treatment based on individual patient profiles, is gaining traction. Innovations in drug delivery systems, such as sustained-release formulations and nanotechnology, aim to enhance the therapeutic effectiveness and minimize side effects of existing medications. As the global burden of peptic ulcers remains significant, the focus on research and development will likely lead to more effective and safer treatment options in the coming years.

Trends

Current trends in peptic ulcer treatment reflect a shift towards more patient-centered approaches and the integration of digital health technologies. There is a growing awareness of the importance of lifestyle modifications, including diet and stress management, as adjuncts to pharmacotherapy. Additionally, the rise of telemedicine has enabled patients to access healthcare professionals more conveniently, leading to improved management of their condition. The market is also witnessing an increase in the use of probiotics and alternative therapies to support gastrointestinal health and enhance the effectiveness of standard treatments. As patients become more involved in their healthcare decisions, the emphasis on holistic treatment approaches is expected to reshape the landscape of peptic ulcer management.

Applications

Peptic ulcer drugs are widely used in various healthcare settings, including outpatient clinics, hospitals, and gastroenterology practices. These medications are essential in managing acute exacerbations of peptic ulcers and preventing complications such as bleeding and perforation. In addition to their primary use in ulcer treatment, some of these drugs are also employed in managing gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome, conditions characterized by excessive stomach acid production. Moreover, the potential for repurposing existing medications for other gastrointestinal disorders is being explored, further broadening their application in clinical practice.

Key Points

Peptic ulcers are primarily caused by H. pylori infection and NSAID use.

Proton pump inhibitors (PPIs) and antibiotics are the mainstay of treatment.

Future therapies may focus on personalized medicine and novel drug combinations.

Digital health technologies and telemedicine are reshaping patient management.

Lifestyle modifications play a crucial role in adjunctive treatment.

The market is exploring the use of probiotics and alternative therapies.

Peptic ulcer drugs are also applicable in treating GERD and Zollinger-Ellison syndrome.

Conclusion

In conclusion, the field of peptic ulcer drug therapy is evolving rapidly, with ongoing research paving the way for new treatment options and approaches. The integration of personalized medicine, lifestyle modifications, and digital health solutions will enhance the management of this prevalent condition. As healthcare providers continue to prioritize patient-centered care, the future holds promise for more effective and holistic strategies in treating peptic ulcers, ultimately leading to improved patient outcomes and quality of life.

[credenceresearchdotblog]

The Gastrointestinal Agents Market is projected to grow from USD 59,863.47 million in 2023 to USD 92,867.89 million by 2032, reflecting a compound annual growth rate (CAGR) of 5.00%.The gastrointestinal (GI) agents market is a rapidly growing sector within the global pharmaceutical industry, driven by the increasing prevalence of gastrointestinal disorders, advancements in drug development, and rising awareness about digestive health. This article explores the key trends, market drivers, challenges, and future outlook of the gastrointestinal agents market.

Browse the full report at https://www.credenceresearch.com/report/gastrointestinal-agents-market

Overview of the Gastrointestinal Agents Market

Gastrointestinal agents are medications used to treat disorders of the digestive system, including conditions like gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), peptic ulcers, Crohn's disease, and ulcerative colitis. These agents are categorized into several classes, such as antacids, proton pump inhibitors (PPIs), H2 receptor antagonists, laxatives, antidiarrheals, and antiemetics. The global gastrointestinal agents market has witnessed significant growth due to the rising incidence of these disorders, coupled with lifestyle changes, aging populations, and increasing adoption of unhealthy diets.

Key Market Drivers

1. Rising Prevalence of Gastrointestinal Disorders: The increasing incidence of GI disorders is a major driver of the market. According to the World Gastroenterology Organization, gastrointestinal diseases affect millions of people worldwide, with a particularly high prevalence in developed countries due to sedentary lifestyles, poor diet, and high levels of stress.

2. Aging Population: The growing aging population is another critical factor contributing to market growth. Older adults are more susceptible to gastrointestinal issues due to age-related changes in the digestive system, making them a key demographic for GI agents.

3. Advancements in Drug Development: Ongoing research and development activities have led to the introduction of novel GI agents that offer improved efficacy and safety profiles. Biologics and targeted therapies, for example, are gaining traction in the treatment of inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis.

4. Increased Awareness and Diagnosis: Enhanced awareness about digestive health and the availability of advanced diagnostic tools have resulted in the early detection and treatment of GI disorders, further boosting the demand for gastrointestinal agents.

5. Rising Healthcare Expenditure: Increased healthcare spending, particularly in emerging economies, has improved access to healthcare services and medications, propelling the growth of the GI agents market.

Challenges Facing the Market

1. Side Effects and Safety Concerns: Many gastrointestinal agents, especially long-term treatments such as PPIs, have been associated with side effects like kidney issues, infections, and bone fractures. Safety concerns can lead to regulatory restrictions and affect market growth.

2. High Cost of Advanced Therapies: The cost of new biologics and targeted therapies can be prohibitive for patients and healthcare systems, particularly in low- and middle-income countries. This cost barrier may limit market expansion in some regions.

3. Generic Competition: The expiration of patents for several blockbuster drugs has led to the entry of generic versions, which, while increasing accessibility, have also intensified competition and put pressure on market prices.

Future Outlook and Opportunities

The gastrointestinal agents market is poised for continued growth, with several opportunities on the horizon:

1. Innovation in Drug Delivery Systems: Innovations in drug delivery systems, such as delayed-release formulations, are expected to enhance the effectiveness of GI agents and improve patient compliance.

2. Personalized Medicine: The development of personalized medicine approaches, where treatment is tailored based on genetic and environmental factors, is gaining momentum. This approach promises to optimize treatment outcomes for GI disorders, particularly IBD.

3. Expansion in Emerging Markets: Emerging markets, including Asia-Pacific and Latin America, offer significant growth opportunities due to improving healthcare infrastructure, increasing disposable incomes, and growing awareness about GI disorders.

4. Digital Health and Remote Monitoring: The integration of digital health technologies and remote monitoring solutions is expected to improve the management of chronic GI conditions, enabling better patient outcomes and driving the demand for GI agents.

Key Player Analysis

Johnson & Johnson

Pfizer Inc.

AstraZeneca

AbbVie Inc.

Takeda Pharmaceuticals

Bayer AG

GlaxoSmithKline plc.

Sanofi

Allergan

Boehringer Ingelheim

Segments:

Based on Type:

Dietary Supplements

Drugs

Antacids

Anti-diarrheal Agents

Anti-emetics

H2 Blockers

Laxatives

Proton Pump Inhibitors

Based on Disease Type:

Constipation

Diarrhoea

Gastroesophageal Reflux Disease

Inflammatory Bowel Disease

Peptic Ulcer Disease

Based on Route of Administration:

Oral

Parenteral

Rectal

Based on End-User:

Homecare

Hospitals & Clinics

Based on Distribution Channel:

Offline Pharmacies

Online Pharmacies

 Based on the Geography:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/gastrointestinal-agents-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[blog-site-for-market-research]

Outlook on the Evolving GERD & NERD Treatment Market

Market Overview –

Over the course of the forecast period, 2023–2030, the Americas GERD & NERD therapy market is anticipated to increase USD 4.99 at a CAGR of 6.20%.

The GERD & NERD treatment market is evolving to meet the needs of individuals suffering from gastroesophageal reflux disease (GERD) and non-erosive reflux disease (NERD). With a focus on NERD reflux treatment, pharmaceutical companies are developing medications to alleviate symptoms like heartburn and acid regurgitation. As awareness grows, there's a rising demand for effective therapies, driving market growth and innovation.

The GERD (Gastroesophageal Reflux Disease) and NERD (Non-Erosive Reflux Disease) treatment market addresses medical interventions aimed at managing and alleviating symptoms associated with these gastrointestinal disorders. GERD involves chronic acid reflux, causing heartburn, regurgitation, and other symptoms, while NERD presents similar symptoms without visible esophageal damage. This market encompasses various treatment options, including medications, lifestyle modifications, and surgical interventions, tailored to the severity and underlying causes of reflux.

A key driver of the GERD & NERD treatment market is the high prevalence of these disorders globally, attributed to factors such as obesity, poor dietary habits, smoking, and genetic predisposition. As awareness of GERD & NERD increases among both patients and healthcare providers, there is a growing demand for effective treatment options to alleviate symptoms and improve quality of life.

Advancements in medical technology and pharmaceuticals have led to the development of novel treatment approaches for GERD & NERD. Proton pump inhibitors (PPIs), H2 receptor antagonists, antacids, and prokinetic agents are commonly used medications to reduce gastric acid production and alleviate symptoms. Additionally, minimally invasive procedures like endoscopic therapies and surgical interventions offer alternatives for patients with refractory symptoms or complications.

The COVID-19 pandemic has impacted the GERD & NERD treatment market, with disruptions in healthcare services, changes in patient behavior, and challenges in accessing specialized care. However, telemedicine and remote consultations have emerged as valuable tools in managing GERD & NERD, enabling patients to receive timely advice and prescriptions from healthcare providers.

Segmentation –

Americas GERD & NERD treatment market is segmented on the basis of drug class, dosage form, and end user. On the basis of drug class, the market is segmented into antacids (acid neutralizers), proton pump inhibitors, H2 receptor blocker, prokinetic agents, antidepressants, calcium channel blockers, and others. Proton pump inhibitors are further segmented into esomeprazole, omeprazole, pantoprazole, lansoprazole, dexlansoprazole, rabeprazole, and others. H2 receptor blocker is further segmented into ranitidine, famotidine, cimetidine, nizatidine, and others. Prokinetic agents are further segmented into domperidone, metoclopramide, itopride, prucalopride, cisapride, benzamide, mosapride, erythromycin, and others. Based on the dosage form, it is segmented into solid and liquid. On the basis of the end user, it is segmented into hospitals & clinics, research centers, and others.

Regional Analysis –

The GERD (Gastroesophageal Reflux Disease) and NERD (Non-Erosive Reflux Disease) treatment market varies regionally due to differences in disease prevalence, treatment guidelines, and healthcare infrastructure. In developed regions like North America and Europe, where there is a higher incidence of GERD and NERD, the market for acid-suppressive medications, lifestyle modifications, and minimally invasive procedures is well-established, with a focus on symptom relief and disease management. Conversely, in developing regions with limited access to gastroenterology specialists and diagnostic tools, such as parts of Africa and Asia-Pacific, the market for GERD and NERD treatment is still evolving, with challenges related to underdiagnosis and undertreatment. Moreover, cultural dietary habits and healthcare-seeking behaviors influence patient adherence to treatment regimens and healthcare utilization patterns across different regions. As awareness of GERD and NERD risks grows globally, there is a growing opportunity for market expansion through education, early intervention, and investment in gastroenterology services to improve outcomes for patients with acid reflux disorders worldwide.

Key Players –

GERD & NERD treatment major players in the Americas include AstraZeneca Plc (U.K), Boston Scientific Corporation (U.S.), Cempra Inc. (U.S.), Eisai Co., Ltd. (Japan), EndoGastric Solutions Inc. (U.S.), EndoStim Inc. (U.S.), GlaxoSmithKline Plc (U.K), Ironwood Pharmaceuticals, Inc. (U.S.), Jeil pharmaceutical Co. Ltd. (South Korea), Johnson & Johnson (U.S.), Mederi Therapeutics Inc. (U.S.), Medigus Ltd. (Israel), Medtronic Inc. (U.S.), Merck & CO., Inc. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceuticals Industries Limited (Israel), Torax Medical (U.S.), Valeant Pharmaceuticals International, Inc. (Canada), Carbon Medical technologies (U.S.), Allegiant health (U.S.), Tya pharmaceuticals (U.S.), and Sanofi (France).

Related Reports –

Pain Patch

Electronic Trial Master File Systems

Neurology Devices

Medical Payment Fraud Detection

For more information visit at MarketResearchFuture

[myblogscmi]

Global Gastritis Treatment Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Gastritis

The global Gastritis Treatment Market is estimated to be valued at USD 162.2 million in 2021 and is expected to exhibit a CAGR of 4% over the forecast period 2022-2029, as highlighted in a new report published by Coherent Market Insights. A) Market Overview: Gastritis is a condition characterized by the inflammation of the lining of the stomach. It can be caused by various factors such as infection, excessive alcohol consumption, prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs), and autoimmune diseases. The Gastritis Treatment Market products includes pharmaceutical drugs, proton pump inhibitors (PPIs), H2 receptor antagonists, antacids, and antibiotics. The need for gastritis treatment products arises due to the increasing prevalence of gastritis worldwide. According to the World Gastroenterology Organisation (WGO), gastritis affects approximately 50% of the global population. The rising incidence of risk factors such as H. pylori infection, unhealthy lifestyle habits, and the growing aging population contribute to the increasing demand for gastritis treatment products. B) Market Key Trends: One key trend in the gastritis treatment market is the increasing adoption of combination therapy. Combination therapy involves the simultaneous use of two or more drugs to achieve a synergistic effect in treating gastritis. This approach helps in improving treatment outcomes and reducing the risk of drug resistance. For instance, a combination therapy of proton pump inhibitors and antibiotics is often prescribed for the eradication of H. pylori infection. The use of combination therapy is expected to drive market growth during the forecast period. Technological: The development of advanced diagnostic techniques such as endoscopy and molecular tests has improved the accuracy and efficiency of gastritis diagnosis, leading to better treatment outcomes. D) Key Takeaways: 1: The global gastritis treatment market is expected to witness high growth, exhibiting a CAGR of 4% over the forecast period. This growth can be attributed to increasing prevalence of gastritis and the rising demand for treatment products. The market is driven by factors such as H. pylori infection, unhealthy lifestyle habits, and the growing aging population. 2: In terms of regional analysis, North America is expected to dominate the gastritis treatment market due to the high prevalence of gastritis in the region. Asia Pacific is anticipated to be the fastest-growing region, owing to the increasing healthcare expenditure and improving healthcare infrastructure in countries like India and China. 3: Key players operating in the global gastritis treatment market include Otsuka Indonesia PT, AstraZeneca PLC, Zydus Cadila Healthcare Limited, Novartis AG, and others. These companies focus on product development, partnerships, and collaborations to strengthen their market position. In conclusion, the global gastritis treatment market is projected to grow significantly over the forecast period. Increasing prevalence of gastritis and the adoption of combination therapy are key trends driving market growth. Political initiatives, economic factors, changing social habits, and technological advancements further contribute to the expansion of the market. North America is expected to dominate the market, while Asia Pacific is anticipated to witness the highest growth. Key players in the market include Otsuka Indonesia PT, AstraZeneca PLC, Zydus Cadila Healthcare Limited, and Novartis AG, among others.

[chetanare]

Global H2 Receptor Antagonist Market Size, Share, Development, Growth And Demand Forecast To 2026

Global H2 Receptor Antagonist Market Size, Share, Development, Growth And Demand Forecast To 2026

“Global H2 Receptor Antagonist Sales Market (Sales, Revenue and competitors Analysis of Major Market) from 2014-2026” the new research report adds in kandjmarketresearch.com research reports database. This Research Report spread across 105 Pages, with summarizing Top companies and supports with tables and figures.

A fresh specialized intelligence report published by KandJ Market Research with…

[vicky8588]

Anaphylaxis Treatment Market, Size, Share 2021-2028

Market Overview

The Global Anaphylaxis Treatment Market is expected to grow at a high CAGR during the forecasting period (2021-2028).

Anaphylaxis is a severe allergic reaction to the venom, food, or medication. Mostly it is caused by a bee sting or eating foods that are known to cause allergies, such as peanuts or tree nuts. Some of the common causes of anaphylaxis include medication, peanuts, tree nuts, insect stings, fish, shellfish, and milk. Other causes may include exercise and latex.

The primary drug treatments for acute anaphylactic reactions are epinephrine and H1 antihistamines. As per the 2013 World Allergy Association update, 2015 Joint Task Force anaphylaxis update, and 2010 NIAID guidelines, epinephrine is the drug of choice for life-threatening reactions.

Download free sample: https://www.datamintelligence.com/download-sample/anaphylaxis-treatment-market

Market Dynamics

The global anaphylaxis treatment Market growth is driven by several factors such growing prevalence of allergies and their awareness among customers, and increasing advancement in the product with cost-effective solutions.      

Growing cases of anaphylaxis and rising demand for self-administered drugs are driving the market growth.

Rise in patient pool suffering from allergies globally is a major factor driving the anaphylaxis treatment market. In the US and the UK, the incidence of anaphylaxis is 40–500 per million persons, mortality is estimated at 0.63–0.76 per million. In the US, up to 5% population suffers from this condition. The clinical databases such as PubMed have captured the growing prevalence of anaphylaxis.

As per a journal published on NCBI (National Center for Biotechnology Information) in 2017, up to 5% of the U.S. population suffered from the anaphylaxis condition. In addition, around 1% of total hospitalizations and 0.1% of emergency attendances for anaphylaxis would have fatal outcomes. Drugs are a major cause of fatal anaphylaxis in various countries, such as Australia, New Zealand, the U.K., Brazil, and the U.S. As per a journal published on NCBI, in year 2018, the lifetime prevalence of the anaphylaxis is estimated to be 0.05% – 2% in the U.S., and approx. 3% in the Europe. Overall, the fatality of anaphylaxis condition is relatively low across the globe.

Therefore, the growing incidence of anaphylaxis is likely to increase the high uptake of anaphylaxis treatment market.

 COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets.

Lockdown regulations have been relaxed in most countries, but people are reluctant to visit doctors in person, due to the fear of spreading coronavirus (COVID-19). Thus, companies in the anaphylaxis treatment market are adopting telemedicine as individuals prefer remote healthcare services amidst the COVID-19 era. The demand for telehealth technology is expected to rise dramatically during the forecast period. Telemedicine apps are helping to expedite the process of quality medical care in the sphere of warts therapeutics.

Segment Analysis

– By Drug Class

·       Adrenergic Agonists*

·       Antihistamines

·       H2 Receptor Antagonists

·       Bronchodilators

·       Corticosteroids

·       Positive Inotropic Agents

·       Vasopressors

Geographical Analysis

In terms of region, the global anaphylaxis treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America is Expected to Dominate the Global Anaphylaxis Treatment Market

North America accounted for the largest market share of the global anaphylaxis treatment Market in 2019, owing to the rise in patient pool suffering from the condition. In addition, awareness towards the allergic tests and fatalities due to various allergic condition are projected to boost the growth of the anaphylaxis treatment market in this region.  Also, lifestyle changes, early diagnosis of specific allergies, and availability of anaphylaxis treatment are likely to boost the expansion of the anaphylaxis treatment market in North America. Some of the key players in the region are focusing on launching innovative products, including the generic version of epinephrine, for the anaphylaxis condition. This is projected to fuel market growth in in the region. Competitive Landscape

Some of the major players in global anaphylaxis treatment market includes ALK-Abelló A/S, Amneal Pharmaceuticals Inc, Adamis Pharmaceuticals Corporation, Kaleo Inc, Mylan N.V, Novartis International AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., among others. The market players are involved in developing cost-effective and robust solutions to gain market share.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the anaphylaxis treatment market globally. For instance,

Teva Pharmaceutical Industries Ltd has developed an EpiPen which is a generic version of EpiPen Jr and approved by FDA in August 2019. The pen is developed using VIBEX device by Antares Pharma to prevent and provide aid against life-threatening, allergic emergencies including anaphylaxis or any allergic history in genes of patient. The dose of the EpiPen depends on the weight and fitness of the patient or as prescribed by the medical practitioners.

In June 2017, The FDA approved an epinephrine injector product called Symjepi, made by Adamis Pharmaceutical Corp. as the latest alternative to Mylan Pharmaceuticals' EpiPen for the treatment of severe allergic reactions. The product is a 0.3-mg prefilled syringe for the emergency treatment of allergic reactions, including anaphylaxis, for patients who weigh 30 kg (66 pounds) or more.

In July 2018, INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced that its investigational epinephrine nasal spray showed promise in an early clinical trial as a potential needle-free, non-invasive and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis.

Overview:

Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug.

Products:

EpiPen® (epinephrine injection, USP) 0.3 mg Auto-Injectors

Key Developments:

In April 2012, Mylan Inc. and Pfizer Inc. announced that Meridian Medical Technologies, a Pfizer subsidiary, has entered into a settlement agreement with Teva that will resolve pending patent litigation related to its abbreviated new drug application (ANDA) for a generic epinephrine auto-injector.

View Full Report: https://www.datamintelligence.com/research-report/anaphylaxis-treatment-market

Enquiry Before Buying: https://www.datamintelligence.com/enquiry/anaphylaxis-treatment-market

About Us 

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

 For more information: 

Sai Kiran

Sales Manager at DataM Intelligence

Email: info@datamintelligence.com

Tel: +1 877 441 4866

Website: www.datamintelligence.com

[davidwalker2504]

The global Gastroesophageal Reflux Disease (GERD) therapeutics market size was valued at USD 5.66 billion in 2016 and by is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR of -2.9%. Expiration of patented blockbuster drugs, which are indicated for the management of disorders of acid reflux is major restraining factors for this market.

With strong clinical pipelines and patent litigations, the market continues to experience significant changes. Proton pump inhibitors (PPI) and antagonists of histamine H2 receptor have the importance in current scenario of the market.

Upon loss of patent protection of formerly leading branded drugs, generic molecules with low-price can ingest the sales of the branded ones up to 90%. Rising number of companies being exposed to price scrutiny associated with shift in the focus of government on the promotion of consumer convenience will stimulate further reduction of drug prices. Although market turnover is affected by the expiration of major patents and the demand of drugs used to reduce acid, due to the increasing prevalence of heartburn, is anticipated to increase in the upcoming years.

[arorasurbhi]

Expected Growth, Market Analysis, And Regional Analysis Of Peptic Ulcer Drugs Market

Peptic Ulcers:

Peptic Ulcers are a collection of gastrointestinal illnesses that include gastritis, gastric ulcers, duodenal ulcers, and gastroesophageal reflux disease. Drugs that reduce gastric ulcer secretion, such as PPIs and H2 receptor antagonists, and acid neutralization agents, such as antacids and antibiotics against H. pylori infection, are used to treat peptic ulcers. However, for efficient treatment, these medicines are frequently taken in combination.

Market Analysis:

The Peptic Ulcer Drugs Market is expected to increase exponentially, reaching USD 5.13 billion by 2027, with a CAGR of 2.4 percent between 2020 and 2027. The growing prevalence of peptic ulcers, increasing adoption of peptic ulcer drugs over surgery, R&D stimulation through government policies, an increasing number of generic manufacturers of peptic ulcer drugs, changes in disease management, and other factors are driving the global peptic ulcer drugs market.

Furthermore, factors such as the rising prevalence of stress-induced ulcers resulting from changing lifestyles and diets, rising smoking rates, and an aging population are expected to propel the worldwide peptic ulcer medications market to greater heights. However, adverse effects of peptic ulcer drugs, low pipeline productivity, and changes in drug pricing rules are expected to stifle future growth in the global peptic ulcer pharmaceuticals market.

Read More: https://coherentmarketblogs.blogspot.com/2021/07/peptic-ulcer-drugs-market-size-growth.html

[millioninsights]

Gastroesophageal Reflux Disease (GERD) therapeutics market is estimated to be USD 4.34 billion by 2025

Industry Insights

The global Gastroesophageal Reflux Disease (GERD) therapeutics market size was valued at USD 5.66 billion in 2016 and by is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR of -2.9%. Expiration of patented blockbuster drugs, which are indicated for the management of disorders of acid reflux is major restraining factors for this market.

With strong clinical pipelines and patent litigations, the market continues to experience significant changes. Proton pump inhibitors (PPI) and antagonists of histamine H2 receptor have the importance in current scenario of the market.

Upon loss of patent protection of formerly leading branded drugs, generic molecules with low-price can ingest the sales of the branded ones up to 90%. Rising number of companies being exposed to price scrutiny associated with shift in the focus of government on the promotion of consumer convenience will stimulate further reduction of drug prices. Although market turnover is affected by the expiration of major patents and the demand of drugs used to reduce acid, due to the increasing prevalence of heartburn, is anticipated to increase in the upcoming years.

The devices of GERD serves as a substitute for management of heartburn, because of low rate of success and failure in clinical trials. Hence, very limited acceptance of devices of GERD management contribute for the rising demand of drugs having acid neutralizing property, as the major therapy approach.

Nevertheless, the advent of devices which are minimally invasive to address anatomical defects are gaining popularity coupled with supportive evidence from clinical data for performing various procedures including trans oral fundoplication, which helps in preventing reflux of non-acid and acid contents. The adoption of these devices have been further reinforced in the U.S. in 2016 with the advent of a CPT code (43210) which helps in facilitating reimbursement process.

Drug Type Insights

In 2016, market was dominated by the antacids segment and is anticipated to keep its top position over the forecast period. Most preferred first-line therapy for infrequent and mild symptoms is antacids, as the therapy neutralize the secretion of gastric acid immediately. Convenient OTC (over-the-counter) accessibility various forms such as syrups, powders and tablets is accountable for the extreme adoption. Moreover, the AHFS (American Hospital Formulary services), amongst other countries, enlisted over 120 preparations too advocate.

In 2016, the second largest segment was found to be PPIs as it is the most common medication prescription type for the diseases such as heartburn. Generics inflow leading to the loss of exclusiveness of popular drugs, including Prilosec and Nexium, is estimated to negatively affect the sales of branded versions. A further decrease is appearing more with the expected expiration of other patented drugs, such as Dexilant.

Regional Insights

In 2016, the largest region was found to be North America in terms of share for GERD market. Every year, GERD symptoms are experienced by more than 80 million people in the U.S., of which, approximately 25 million patients suffer from acid reflux and heartburn daily and approximately 60 million patients monthly.

Moreover, outpatient clinic visits for GERD disorder in the U.S. has been increased in the past few years because of the more prone geriatric population to develop acid reflux and heartburn. On the contrary, the Asia Pacific is estimated to witness the fastest growth rate. The increasing geriatric population and dietary and lifestyle risk factors such as diet with high fat and obesity, is anticipated to drive the growth. In developing countries, the inclination towards self-medication is quickly increasing because of the affordability and availability of OTC antacids as in China and India.

Competitive Insights

Competitive market, which is generics-driven is creating a pressure on the prices of drug with decreased retail sales, which will stimulate stationary growth in future. Companies producing them range from high to medium on the basis of competitive rivalry. Eisai Co., Ltd.; AstraZeneca PLC; GlaxoSmithKline PLC; Johnson & Johnson and Takeda Pharmaceutical Co., Ltd.; are some of the top key players. In addition, Daewoong Pharmaceutical Co., Ltd.; SRS Pharmaceuticals Pvt. Ltd.; SFJ Pharmaceuticals Group and Ironwood Pharmaceuticals, Inc. are some emerging companies.

Among others, RaQualia Pharma, Inc. and Ironwood Pharmaceuticals, Inc. are focusing more on development of new generic molecules, which involves novel and existing drug mechanisms as a part of the strategy to enter into the competition. Many generic players are also trying to focus on these spaces in an attempt to capture a larger share by the new version to replace the patent expired drugs.  

Read full research report:

https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics-market

Download free request sample:

https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics-market/request-sample

[newinnovationalmarketresearch]

Gastroesophageal Reflux Disease (GERD) Therapeutics Market Share, Top Key Players, Price, Revenue and Growth Rate Forecast 2025

The global Gastroesophageal Reflux Disease (GERD) therapeutics market size was valued at USD 5.66 billion in 2016 and by is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR of -2.9%. Expiration of patented blockbuster drugs, which are indicated for the management of disorders of acid reflux is major restraining factors for this market.

 With strong clinical pipelines and patent litigations, the market continues to experience significant changes. Proton pump inhibitors (PPI) and antagonists of histamine H2 receptor have the importance in current scenario of the market.

 Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics-market/request-sample

 Market Synopsis of Gastroesophageal Reflux Disease (GERD) Therapeutics Market:

 Upon loss of patent protection of formerly leading branded drugs, generic molecules with low-price can ingest the sales of the branded ones up to 90%. Rising number of companies being exposed to price scrutiny associated with shift in the focus of government on the promotion of consumer convenience will stimulate further reduction of drug prices. Although market turnover is affected by the expiration of major patents and the demand of drugs used to reduce acid, due to the increasing prevalence of heartburn, is anticipated to increase in the upcoming years.

 The devices of GERD serves as a substitute for management of heartburn, because of low rate of success and failure in clinical trials. Hence, very limited acceptance of devices of GERD management contribute for the rising demand of drugs having acid neutralizing property, as the major therapy approach.

 Nevertheless, the advent of devices which are minimally invasive to address anatomical defects are gaining popularity coupled with supportive evidence from clinical data for performing various procedures including trans oral fundoplication, which helps in preventing reflux of non-acid and acid contents. The adoption of these devices have been further reinforced in the U.S. in 2016 with the advent of a CPT code (43210) which helps in facilitating reimbursement process.

 Drug Type Insights

 In 2016, market was dominated by the antacids segment and is anticipated to keep its top position over the forecast period. Most preferred first-line therapy for infrequent and mild symptoms is antacids, as the therapy neutralize the secretion of gastric acid immediately. Convenient OTC (over-the-counter) accessibility various forms such as syrups, powders and tablets is accountable for the extreme adoption. Moreover, the AHFS (American Hospital Formulary services), amongst other countries, enlisted over 120 preparations too advocate.

 In 2016, the second largest segment was found to be PPIs as it is the most common medication prescription type for the diseases such as heartburn. Generics inflow leading to the loss of exclusiveness of popular drugs, including Prilosec and Nexium, is estimated to negatively affect the sales of branded versions. A further decrease is appearing more with the expected expiration of other patented drugs, such as Dexilant.

 View Full Table of Contents of This Report @ https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics-market

 Get in touch

At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

[researchreportinsight]

Gastroesophageal Reflux Disease Therapeutics Market 2025: Report Focusing on Opportunities, Revenue & Market Driving Factors

4th January 2021 – The global Gastroesophageal Reflux Disease (GERD)therapeutics market size was valued at USD 5.66 billion in 2016 and by is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR of -2.9%. Expiration of patented blockbuster drugs, which are indicated for the management of disorders of acid reflux is major restraining factors for this market. With strong clinical pipelines and patent litigations, the market continues to experience significant changes. Proton pump inhibitors (PPI) and antagonists of histamine H2 receptor have the importance in current scenario of the market.

Upon loss of patent protection of formerly leading branded drugs, generic molecules with low-price can ingest the sales of the branded ones up to 90%. Rising number of companies being exposed to price scrutiny associated with shift in the focus of government on the promotion of consumer convenience will stimulate further reduction of drug prices. Although market turnover is affected by the expiration of major patents and the demand of drugs used to reduce acid, due to the increasing prevalence of heartburn, is anticipated to increase in the upcoming years.

The devices of GERD serve as a substitute for management of heartburn, because of low rate of success and failure in clinical trials. Hence, very limited acceptance of devices of GERD management contributes for the rising demand of drugs having acid neutralizing property, as the major therapy approach. Nevertheless, the advent of devices which are minimally invasive to address anatomical defects are gaining popularity coupled with supportive evidence from clinical data for performing various procedures including trans oral fundoplication, which helps in preventing reflux of non-acid and acid contents. The adoption of these devices has been further reinforced in the U.S. in 2016 with the advent of a CPT code (43210) which helps in facilitating reimbursement process.

Access Gastroesophageal Reflux Disease (GERD) Therapeutics Market Report with TOC @ https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics-market

In 2016, market was dominated by the antacids segment and is anticipated to keep its top position over the forecast period. Most preferred first-line therapy for infrequent and mild symptoms is antacids, as the therapy neutralizes the secretion of gastric acid immediately. Convenient OTC (over-the-counter) accessibility various forms such as syrups, powders and tablets is accountable for the extreme adoption. Moreover, the AHFS (American Hospital Formulary services), amongst other countries, enlisted over 120 preparations too advocate. In 2016, the second largest segment was found to be PPIs as it is the most common medication prescription type for the diseases such as heartburn. Generics inflow leading to the loss of exclusiveness of popular drugs, including Prilosec and Nexium, is estimated to negatively affect the sales of branded versions. A further decrease is appearing more with the expected expiration of other patented drugs, such as Dexilant.

In 2016, the largest region was found to be North America in terms of share for GERD market. Every year, GERD symptoms are experienced by more than 80 million people in the U.S., of which, approximately 25 million patients suffer from acid reflux and heartburn daily and approximately 60 million patients monthly. Moreover, outpatient clinic visits for GERD disorder in the U.S. has been increased in the past few years because of the more prone geriatric population to develop acid reflux and heartburn. On the contrary, the Asia Pacific is estimated to witness the fastest growth rate. The increasing geriatric population and dietary and lifestyle risk factors such as diet with high fat and obesity, is anticipated to drive the growth. In developing countries, the inclination towards self-medication is quickly increasing because of the affordability and availability of OTC antacids as in China and India.

Competitive market, which is generics-driven is creating a pressure on the prices of drug with decreased retail sales, which will stimulate stationary growth in future. Companies producing them range from high to medium on the basis of competitive rivalry. Eisai Co., Ltd.; AstraZeneca PLC; GlaxoSmithKline PLC; Johnson & Johnson and Takeda Pharmaceutical Co., Ltd.; are some of the top key players. In addition, Daewoong Pharmaceutical Co., Ltd.; SRS Pharmaceuticals Pvt. Ltd.; SFJ Pharmaceuticals Group and Ironwood Pharmaceuticals, Inc. are some emerging companies. Among others, RaQualia Pharma, Inc. and Ironwood Pharmaceuticals, Inc. are focusing more on development of new generic molecules, which involves novel and existing drug mechanisms as a part of the strategy to enter into the competition. Many generic players are also trying to focus on these spaces in an attempt to capture a larger share by the new version to replace the patent expired drugs.

Request a Sample Copy of Gastroesophageal Reflux Disease (GERD) Therapeutics Market Report @ https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics-market/request-sample

[sapanas]

Upper GI series Market Analysis, Share, Size, Trends And Industry Growth

An upper gastrointestinal (UGI) series is radiographic examination of the GI tract for any abnormalities. It is also known as constant radiography. The global upper GI series market by Market Research Future takes a look at the various diseases affecting the GI tract, developments in X-rays, and new projections for the period of 2017 to 2023 (forecast period). The impact of the COVID-19 pandemic and analysis of its effects as well as the opportunities for the technology are also discussed in the report.

Upper GI series market Scope

The global upper GI series market is expected to grow at a CAGR of 4.5% during the forecast period. Huge prevalence of GI disorders is one of the primary drivers of the market. The large healthcare expenditure allocated to detection of GI distress can fuel the market. GI disorders had accounted for close to USD 110 billion in 2005 in the U.S. alone. The interest of the pharmaceutical industry as well as large patient pool can be lucrative for the market in the long run.

Developments in cost-effective treatments, government research for GI disorders, and the large geriatric populace are other drivers of the market. Effective treatments such as acid suppressants, histamine H2 receptor antagonists, and proton pump inhibitors are expected to drive the market to great heights.

But high costs of treatment can impair market growth.

Upper GI series market Segmentation

The global upper GI series market is segmented by test type, imaging material, application, and end users.

On the basis of test type, it is divided into standard barium upper GI series and double-contrast upper GI series.

On the basis of imaging material, the market is segmented into barium swallow, barium follow-through, and barium meal. The barium swallow segment is likely to fetch huge returns for the global upper GI series market owing to its ability to detect abnormalities in esophagus, stomach, and intestines.

On the basis of application, the market is segmented into ulcers, esophageal reflux, esophageal varices, hiatal hernias, and others.

On the basis of end users, it is segmented into hospitals, clinics & laboratories, and others.

Upper GI series market Regional Analysis

Geographically, the global upper GI series market looks at the regions of the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).

The Americas accounted for the largest market share for upper GI series. Factors driving market growth are the large patient population, well-developed healthcare, and increasing geriatric population. Reimbursement policies as well as adoption of advanced diagnostic methods can create plenty of opportunities for the upper GI series market. Approval of the use of disposable devices has paved the way for new strides for the industry in the region. Recently, Boston Scientific gained approval for the use of disposable duodenoscopes for diagnosis of bile duct disorders in the U.S.

Europe is the second largest market, followed by Asia Pacific. The region is expected to be lucrative due to revised codes to be outlined for upper GI series by reputed healthcare associations. A well-developed healthcare network and trained personnel in radiography can facilitate the growth of the upper GI series market.

APAC is the fastest growing market for upper GI series due to presence of many developing countries and cost effective treatments. Change in eating habits and alarming cases of hepatitis C can spur the need for constant radiography. Lastly, the MEA region has the least market share.

Upper GI series market Competition

GastroIntestinal Specialists LLC., Alfa Wassermann SPA, Cadila Pharmaceuticals Limited, Purdue Pharma L.P., Novadaq Technologies Inc., AstraZeneca, Eisai Co., Ltd, and Ironwood Pharmaceuticals Inc. are key players of the global upper GI series market.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/upper-gi-series-market-826

[adwaitcoherent]

By 2026, Ranitidine Market To Surpass US$ 485.4 Million - Coherent Market Insights

Ranitidine Market To to exhibit a CAGR of 1.8% over the forecast period (2018 - 2026).

Request for Sample PDF Copy:

https://www.coherentmarketinsights.com/insight/request-pdf/2131

Description:

Healthcare professionals have been keenly interested in the treatment of gastroesophageal reflux disease (GERD) and stomach & intestinal ulcer owing to its increasing prevalence. GERD is common health problem, which leads to serious medical complications and further huge medical expense in its diagnosis and treatment. The two most frequently observed symptoms associated with GERD are heartburn and acid regurgitation. Usually, over-the-counter antacids, proton pump inhibitor, and H-2 receptor blockers are used to decrease the effects of stomach acids or to block acid production.

 Ranitidine is a histamine H2 antagonists and available as both over-the-counter (OTC) and prescription drug, indicated in the treatment of gastroesophageal reflux disease (GERD). Ranitidine decreases the acid production from stomach for up to 12 hours. Also, ranitidine is commonly used in erosive esophagitis, peptide ulcer disease, and Zollinger–Ellison syndrome. It could be taken orally or intravenously.

 The global ranitidine market size was valued at US$ 412.4 Mn in 2017, and is expected to witness a CAGR of 1.8% over the forecast period (2018 – 2026).

 Global Ranitidine Market Share (%), By Application: 2018 & 2026

Ranitidine  | Coherent Market Insights

 Source: Coherent Market Insights Analysis (2018)

 Growing Research and Development (R&D) on Ranitidine is expected to Boost Market Growth  

 Various government and private research organizations are increasingly engaged in research and development studies to increase the efficacy of ranitidine and examine possible potential of ranitidine to increase future scope of ranitidine market.

 Furthermore, various clinical trials are currently undergoing to identify and compare efficacy between ranitidine and other proton pump inhibitors such as esomeprazole and rabeprazole to measure gastric acid reduction in stomach. With the result of these studies, the efficacy of ranitidine is expected to improve and offer better treatment regimes in reducing excessive gastric acid production in the near future.

 For instance, in November 2015, a study to compare the efficacy of rabeprazole extended release (ER) 50 mg versus ranitidine 150 mg in treating erosive gastroesophageal reflux disease (eGERD) is currently in Phase III clinical stage.

  Global Ranitidine Market Share (%), By Form: 2018 & 2026

Ranitidine  | Coherent Market Insights

 Source: Coherent Market Insights Analysis (2018)

 Rising Cases of Various Gastric Ulcers and Digestive Diseases is expected to Increase Growth of the market  

 High prevalence of gastroesophageal reflux disease (GERD), intestinal & stomach ulcers, esophagitis, heartburn, and other digestive diseases due to unhealthy lifestyle, changing dietary patterns will lead to increase in demand for ranitidine-based medications in the near future. According to Florida Hospital, 2018 U.S. data statistics, in the U.S. over 60 million adults suffer from acid reflux symptoms every month. Furthermore, the source states that each day an estimated 25 million of the 60 million adults suffers from acid reflux symptoms. Also, according to the same source, about 20% of people with acid reflux will develop gastroesophageal reflux disease (GERD) in the near future.

 Heartburn with or without regurgitation is identified as one of the prime symptoms of gastroesophageal reflux disease (GERD). According to World Gastroenterology Organization (WGO), 2015, prevalence of GERD is rapidly increasing worldwide, with differences reported in prevalence ranging from 2.5% to 6.6% in Eastern Asia while slightly higher up to 13.8% to 25.8% in North America.    

 The reason for high prevalence of GERD is not entirely clear, however, it appears to be correlated with increasing prevalence of obesity, and several dietary factors. In obese patients, excess belly fat exert more pressure on the stomach, which causes backflow of acid causing heartburn. Increasing number of obese patients across the globe will indirectly increase GERD cases and this is expected to fuel growth of ranitidine market. According to World Health Organization (WHO), in 2016, over 1.9 billion adults aged 18 years and above were overweight, of which over 650 million were obese, worldwide. Furthermore, GERD is associated with possible risk of Barrett’s esophagus: a premalignant condition that damages the esophagus tube.  

 However, stringent regulatory guidelines of FDA in the manufacturing of finished drugs will limit growth of ranitidine market. For instance, in March 2018, the Ministry of Food and Drug Safety, South Korea banned the imports of 150 mg Zantac (ranitidine) supplied by GlaxoSmithKline (GSK) Korea, for 4 months (March to June 2018) due to its different shape and coatings. According to the same source, South Korea’s Ministry of Food and Drug Safety report, GSK violated Pharmaceutical Affairs Act by changing the approved shape of Zantac. Zantac is supposed to be white and round with thin film-coatings on both side, while GSK distributed Zantac with thick coated film and also coating around some of the tablets were slightly broken. Changes in color, taste, and packaging might hurt the safety and efficacy of drugs, which directly affects the quality of product.  

 Furthermore, one of the major challenges in determining prevalence of GERD is to identify the patients’ suffering with the condition. Patients suffering with GERD-related symptoms do not consult healthcare professionals until the symptom gets severe. . Direct costs associated with GERD disease include costs of over-the-counter and prescription medications, physician office and hospital visits, surgical costs, and costs of treating other possible complications such as Barrett's esophagus and esophageal adenocarcinoma, which may result from the disease. This is expected to limit the growth of ranitidine market, over the forecasted period.    

 Key players operating in the global ranitidine market include GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Strides Pharma Science Limited (StridesShasun), Tocris Bioscience (R & D Systems), Merck KGaA, and Sun Pharmaceutical Industries Limited among others.

About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.

 Buy Report Here:

https://www.coherentmarketinsights.com/insight/buy-now/2131

Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave.  #3200  Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[medicalnewstoday]

New report: Global H2 Receptor Antagonist Market  revenues to rake in at a CAGR of 6%    during  2019-2029

Sinusitis Treatment Market Forecast

Based on the route of administration, the sinusitis treatment market is classified as oral, nasal, topical, and injectable. With a wide range of drug classes in the sinusitis treatment market, such as OTC and prescription drugs, the distribution channel segment of the sinusitis treatment market is further segmented into hospital pharmacies, retail pharmacies, specialty clinics, and online pharmacies. Increase in the patient pool in China, India, as well as an increase in the prevalence of sinusitis in North America make these regions among the fastest-growing sinusitis treatment markets. Furthermore, rigorous research and development activities and increase in the number of factors that are predisposing people to sinusitis are also estimated to offer significant revenue-generating opportunities for the sinusitis treatment market during the forecast period.

Request for Check Discount @ https://www.xploremr.com/connectus/check-discount/4007

Global Sinusitis Treatment Market: Competitive Landscape

This section of the sinusitis treatment market report features the profiles of the key players operating in the sinusitis treatment market based on their marketing and differential strategies.

Examples of some of the key players featured in this report are

Sanofi, Bayer AG

Abbott Laboratories

Eli Lily and company

Merck & Co, Inc.

AstraZeneca Plc

Dr. Reddy’s Laboratories Ltd

Novartis AG

Sun Pharmaceuticals

Pfizer Inc.

Key players in the sinusitis treatment market are keen on upgrading their existing service portfolio and strategies to meet not only service demand, but also dominate the regional market. Many regional & international collaborations between developed and developing nations around the world for sinusitis treatment are anticipated to increase the number of facilities and services. Key service players are focused on adopting new strategies & policies, increasing point of sales & service agreements, and promoting research & development collaborations across academia and research institutes. Furthermore, continuous new service lunches, joint ventures, partnerships, and mergers & acquisitions are expected to boost the growth of the sinusitis treatment market.

Request Methodology of this report @ https://www.xploremr.com/connectus/request-methodology/4007

Global Sinusitis Treatment Market: Additional Questions Answered

Some of the additional questions addressed in this report on the global sinusitis treatment market are as follows:

What is the revenue potential of the sinusitis treatment market across North America, Europe, and East Asia?

Who are the key competitors and what are their portfolios in sinusitis treatment market?

What are the major challenges influencing the growth of the sinusitis treatment market?

How is intervention from regulatory authorities shaping the growth of the sinusitis treatment market?

About us:

XploreMR is one of the world’s leading resellers of high-quality market research reports. We feature in-depth reports from some of the world’s most reputed market research companies and international organizations. We serve across a broad spectrum – from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Our team comprises an eclectic mix of experienced market research specialists, search engine specialists, web designers, online marketers, and business writers. The team is highly committed to going above and beyond, and serving the research needs of our clientele.

Contact us:

111 North Market Street, Suite 300,

San Jose, CA 95113, United States

Tel: +1-669-284-0108

E-mail: sales@xploremr.com

Website: www.xploremr.com

[ihealthcareanalyst]

Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast 2018-2023

Scleroderma is an autoimmune disease affecting the skin and other organs of the body. There are two main types of the disease: the localized form (called localized scleroderma, limited scleroderma, or morphea) and the systemic form (called systemic scleroderma, diffuse scleroderma, generalized scleroderma, or systemic sclerosis). Laboratory testing can identify antitopoisomerase or anticentromere antibodies. X-rays and computerized tomography (CT) scans are used to look at bone abnormalities. Thermography can detect differences in skin temperature between the lesion and normal tissue. Ultrasound and magnetic resonance imaging (MRI) can aid soft tissue assessment. There are no treatments for scleroderma itself, but organ system–specific complications are treated and relief of symptoms is often achieved with vasodilators such as calcium channel blockers, alpha blockers, serotonin receptor antagonists, angiotensin II receptor inhibitors, statins, local nitrates or iloprost. Effective treatments are available for those with severe disease, including acute kidney disease, pulmonary hypertension, lung inflammation and gastrointestinal problems. Browse Scleroderma Diagnostics and Therapeutics Market by Indication (Localized, Systemic), Test Type (Blood Tests, Electrocardiogram and Echocardiogram, Imaging Techniques, Pulmonary Function Tests, Skin Biopsy), Drug Class (Calcium Channel Blockers, Chelating Agents, Corticosteroids, Endothelin Receptor Agonists, Immunosuppressive Agents, PDE-5 Inhibitors, Prostacyclin Analogues, ACE Inhibitors, H2 Blockers, Proton Pump Inhibitors) and Forecast 2018-2023 at https://www.ihealthcareanalyst.com/report/scleroderma-diagnostics-therapeutics-market/ The global scleroderma diagnostics and therapeutics market segmentation is based on indication (localized, systemic), test type (blood tests, electrocardiogram and echocardiogram, imaging techniques, pulmonary function tests, skin biopsy), drug class (calcium channel blockers, chelating agents, corticosteroids, endothelin receptor agonists, immunosuppressive agents, PDE-5 inhibitors, prostacyclin analogues, ACE inhibitors, H2 blockers, proton pump inhibitors). The global scleroderma diagnostics and therapeutics market report provides market size (Revenue US$ Million 2018-2023), market share, trends and forecasts growth trends (CAGR%, 2018-2023). The global scleroderma diagnostics and therapeutics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global scleroderma diagnostics and therapeutics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market. Major players operating in the global scleroderma diagnostics and therapeutics market and profiled in this report include Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Corbus Pharmaceutical Holdings Inc., Cytori Therapeutics, Inc., Cumberland Pharmaceuticals, Inc., F. Hoffmann La Roche Ltd., Gilead Sciences, Inc., Merck KGaA, Pfizer, Inc., and Sanofi. 1. Indication 1.1. Localized 1.2. Systemic 2. Test Type 2.1. Blood Tests 2.2. Electrocardiogram and Echocardiogram 2.3. Imaging Techniques 2.4. Pulmonary Function Tests 2.5. Skin Biopsy 3. Drug Class 3.1. Calcium Channel Blockers 3.2. Chelating Agents 3.3. Corticosteroids 3.4. Endothelin Receptor Agonists 3.5. Immunosuppressive Agents 3.6. PDE-5 Inhibitors 3.7. Prostacyclin Analogues 3.8. Others (ACE Inhibitors, H2 Blockers, Proton Pump Inhibitors, etc.) 4. Geography (Region, Country) 4.1. North America (U.S., Canada) 4.2. Latin America (Brazil, Mexico, Rest of LA) 4.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 4.4. Asia Pacific (Japan, China, India, Rest of APAC) 4.5. Rest of the World 5. Company Profiles 5.1. Actelion Pharmaceuticals, Inc. 5.2. Bayer AG 5.3. Boehringer Ingelheim 5.4. Corbus Pharmaceutical Holdings, Inc. 5.5. Cumberland Pharmaceuticals Inc. 5.6. Cytori Therapeutics, Inc. 5.7. F. Hoffmann La Roche Ltd. 5.8. Gilead Sciences, Inc. 5.9. Merck KGaA 5.10. Pfizer, Inc. 5.11. Sanofi To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/scleroderma-diagnostics-therapeutics-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com

[rohinic123-blog]

H2-Receptor Antagonists Market to Garner Brimming Revenues by 2030

H2-Receptor Antagonists Market: Introduction

Histamine H2 receptor antagonist, also known as H2-blockers, are a class of medications that are used in the treatment of acid-peptic disease including duodenal and gastric ulcers, inflamed stomach gastroesophageal reflux disease, common heartburn, and peptic ulcers. These medications are available over-the-counter (OTC) and with the doctor’s prescription. Common H2 receptor blockers include nizatidine, famotidine, and cimetidine.

In April 2020, the Food and Drug Administration (FDA) recalled all forms of withdrawal prescription and over-the-counter (OTC) ranitidine drugs from the U.S. market immediately. This recommendation was made, as unacceptable levels of N-nitrosodimethylamine (NDMA), a probable carcinogen (cancer-causing chemical), were found in some ranitidine products.

Report Overview @

https://www.transparencymarketresearch.com/h2-receptor-antagonists-market.html

Key Drivers and Restraints of Global H2-Receptor Antagonists Market

High prevalence and increasing incidence of duodenal and gastric ulcers, inflamed stomach gastroesophageal reflux disease, and peptic ulcer disease in developed countries has led to the development of novel therapeutics drugs. Biopharmaceutical companies have made significant investments in R&D activities, and a large number of pipeline products are at different stages of clinical approvals, which are likely to commercialize during the forecast period.

Planning To Lay Down Future Strategy? Request Brochure Of H2-Receptor Antagonists Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=77626

According to International Foundation for Gastrointestinal Disorders, Inc., the prevalence of gastroesophageal reflux disease (GERD) was 18.1% to 27.8% in North America, 8.8% to 25.9% in Europe, 2.5% to 7.8% in East Asia, 8.7% to 33.1% in the Middle East, 11.6% in Australia, and 23.0% in South America in 2019. GERD is a chronic and highly prevalent disorder that can potentially lead to serious medical complications, and the medical expense involved in the diagnosis, treatment, and management of the disease is significant.

Rising awareness about gastroesophageal reflux disease and acid-peptic disease, availability of treatment options, and management of these diseases, have increased the demand for the treatment of H2-receptor antagonists in developing countries. Governments and other non-profit organizations spread awareness and educate people about gastric acid management through campaigns and educational and clinical workshops.

Retail pharmacies is projected to be a highly attractive segment during the forecast period. Rising chain of retail pharmacies and easy access to these pharmacies are likely to propel the segment during the forecast period. Moreover, retail pharmacies are considered as the first point of contact for self-medication. Easy availability of pharmaceutical drugs and some integrin antagonists at retail pharmacies is projected to drive the retail pharmacies segment during the forecast period.

To Obtain All-Inclusive Information On Forecast Analysis Of H2-Receptor Antagonists Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=77626

Asia Pacific to Lead Global H2-Receptor Antagonists Market

In terms of geography, the global H2-Receptor Antagonists market can be segmented into five key regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are expected to hold major share of the global H2-receptor antagonists market during the forecast period, owing to developed health care infrastructure and large patient population along with increasing technological development in these regions.

Increase in government intervention in emerging markets has led to a surge in awareness about diseases and improvement in health care infrastructure. Additionally, socioeconomic development has been observed in emerging economies across Asia, Africa, and Latin America. These factors contribute to the overall increase in spending capacity of the population.

Request For Covid19 Impact Analysis –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=77626

Key Players Operating in Global H2-Receptor Antagonists Market

Manufacturers operating in the global H2-receptor antagonists market are increasingly investing in research & development of new and innovative techniques for new and improved dosage foam. These players are also focused on offering highly efficient and patient compliant products.

Leading companies operating in the global H2-receptor antagonists market are:

Perrigo Company plc

Mylan N.V.

Fresenius SE & Co. KgaA

Teva Pharmaceutical

Apotex Inc.

AbbVie

Takeda

Roche

Celgene

Galapagos

Eli Lilly

Pfizer

EA Pharma Co. Ltd.

InDex Pharma

More Trending Reports by Transparency Market Research –

Ozone Therapy in Dermatology Market -

https://www.prnewswire.co.uk/news-releases/tmr-projects-strong-growth-for-ozone-therapy-in-dermatology-market-advanced-ozone-generators-to-drive-5-0-cagr-led-growth-during-2019-2027-893684835.html

Ophthalmic Surgical Technologies Market –

https://www.biospace.com/article/ophthalmic-surgical-technologies-market-femtosecond-systems-likely-to-dominate-the-market/